Solvent/polymer solutions as suspension vehicles
View Patent ↗A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be selected from the group consisting of benzyl benzoate, decanol, ethyl hexyl lactate, and mixtures thereof and the at least one polymer may be selected from the group consisting of a polyester, pyrrolidone, ester of an unsaturated alcohol, ether of an unsaturated alcohol, polyoxyethylenepolyoxypropylene block copolymer, and mixtures thereof. In one embodiment, the at least one solvent is benzyl benzoate and the at least one polymer is polyvinylpyrrolidone. A stable, nonaqueous suspension formulation that includes the nonaqueous, single-phase vehicle and an active agent, and a method of forming the same, are also disclosed.
1. An implantable osmotic drug delivery device, comprising:
a reservoir containing a stable, nonaqueous suspension formulation, the suspension formulation comprising
a particle formulation comprising an active agent and an excipient, wherein the active agent comprises a peptide, polypeptide, or protein, and the excipient comprises methionine, and
a nonaqueous, single-phase vehicle consisting essentially of about 10% to about 90% (w/w) polyvinylpyrrolidone and about 90% to about 10% (w/w) benzyl benzoate,
wherein the vehicle has a viscosity of between approximately 10,000 poise to approximately 20,000 poise measured at 37° C.;
a semipermeable membrane;
an osmotic engine;
a piston; and
a diffusion moderator.
2. The implantable osmotic drug delivery device of claim 1 , wherein the particle formulation comprises one or more additional excipients.
3. The implantable osmotic drug delivery device of claim 2 , wherein the one or more additional excipients are selected from the group consisting of citrate buffer, sucrose, succinate, and dextran.
4. The implantable osmotic drug delivery device of claim 3 , wherein the one or more additional excipients comprise sucrose and citrate buffer.
5. The implantable osmotic drug delivery device of claim 1 , wherein the single-phase vehicle consists essentially of about 25% to about 75% (w/w) polyvinylpyrrolidone and about 75% to about 25% (w/w) benzyl benzoate.
6. The implantable osmotic drug delivery device of claim 1 , wherein the particle formulation is formed by lyophilization, spray-drying, or freeze-drying.
7. The implantable osmotic drug delivery device of claim 1 , wherein the particle formulation is present in the suspension formulation in a range from approximately 0.1 to 50% (w/w).
8. The implantable drug delivery device of claim 1 , wherein the implantable drug delivery device is not primed before use.
9. A method of making the implantable osmotic drug delivery device of claim 1 , the method comprising:
assembling the reservoir, the suspension formulation, the semipermeable membrane, the osmotic engine, the piston, and the diffusion moderator to form the implantable osmotic drug delivery device.
10. The method of claim 9 , wherein the assembling further comprises lubricating the reservoir and the piston with silicon fluid before insertion of the piston into the reservoir.
11. The method of claim 9 , wherein the osmotic engine comprises osmotic tablets and polyethylene glycol adjacent the piston, and the assembling further comprises dispensing polyethylene glycol into the reservoir and inserting the osmotic tablets.
12. The method of claim 11 , wherein after the inserting of the osmotic tablets the semipermeable membrane is inserted into a first end of the reservoir adjacent the osmotic tablets.
13. The method of claim 12 , wherein after the semipermeable membrane is inserted the suspension formulation is loaded into the reservoir through a second end of the reservoir.
14. The method of claim 13 , wherein after the suspension formulation is loaded the diffusion moderator is inserted into the second end of the reservoir.
15. A method of using the implantable osmotic drug delivery device of claim 1 , the method comprising:
implanting the osmotic drug delivery device in a subject, wherein the osmotic drug delivery device is not primed before implantation.
16. A method of making an implantable osmotic drug delivery device, the method comprising:
lubricating a reservoir and a piston with silicon and inserting the piston into the reservoir;
dispensing polyethylene glycol into the reservoir and inserting osmotic tablets into the polyethylene glycol in the reservoir, wherein the osmotic tablets are adjacent the piston;
inserting a semipermeable membrane into a first end of the reservoir, wherein the semipermeable membrane is adjacent the osmotic tablets;
loading a suspension formulation into the reservoir through a second end of the reservoir, wherein the suspension formulation is a nonaqueous suspension formulation comprising
a particle formulation comprising an active agent and an excipient, wherein the active agent comprises a peptide, polypeptide, or protein, and the excipient comprises methionine, and
a nonaqueous, single-phase vehicle consisting essentially of about 10% to about 90% (w/w) polyvinylpyrrolidone and about 90% to about 10% (w/w) benzyl benzoate,
wherein the vehicle has a viscosity of between approximately 10,000 poise to approximately 20,000 poise measured at 37° C.; and
inserting a diffusion moderator into a second end of the reservoir, wherein the diffusion moderator is adjacent the suspension formulation.